Results 311 to 320 of about 22,643,381 (355)
Some of the next articles are maybe not open access.
Pediatrics In Review, 1991
Hemophilia is a hereditary bleeding disorder characterized by Factor VIII (F-VIII) or Factor IX (F-IX) deficiency, bleeding into joints and soft tissues, and an X-linked mode of inheritance. Approximately one third of new cases occur as spontaneous mutations, with no family history of hemophilia.
J M, Lusher, I, Warrier
openaire +2 more sources
Hemophilia is a hereditary bleeding disorder characterized by Factor VIII (F-VIII) or Factor IX (F-IX) deficiency, bleeding into joints and soft tissues, and an X-linked mode of inheritance. Approximately one third of new cases occur as spontaneous mutations, with no family history of hemophilia.
J M, Lusher, I, Warrier
openaire +2 more sources
Emergency Medicine Clinics of North America, 1993
Hemophilia and von Willebrand's disease are the most common hereditary bleeding disorders. A variety of treatment modalities of these disorders are discussed. Common organ system bleeding and its treatment and disposition are outlined. Finally, potential complications of both the disease and treatment are reviewed.
J A, Pfaff, M, Geninatti
openaire +2 more sources
Hemophilia and von Willebrand's disease are the most common hereditary bleeding disorders. A variety of treatment modalities of these disorders are discussed. Common organ system bleeding and its treatment and disposition are outlined. Finally, potential complications of both the disease and treatment are reviewed.
J A, Pfaff, M, Geninatti
openaire +2 more sources
Hematology/Oncology Clinics of North America, 1992
Over the past few years considerable progress has been made in elucidating the molecular genetics of hemophilia A, in carrier detection and prenatal diagnosis, and in the production of safer clotting factor concentrates. Recombinant FVIII, shown to be safe and effective in ongoing prelicensure clinical trials that began in the spring of 1987, should ...
J M, Lusher, I, Warrier
openaire +2 more sources
Over the past few years considerable progress has been made in elucidating the molecular genetics of hemophilia A, in carrier detection and prenatal diagnosis, and in the production of safer clotting factor concentrates. Recombinant FVIII, shown to be safe and effective in ongoing prelicensure clinical trials that began in the spring of 1987, should ...
J M, Lusher, I, Warrier
openaire +2 more sources
Pediatric Clinics of North America, 1980
The clinical manifestations of hemophilia depend upon both age and the severity of the factor VIII or IX deficiency. Hemophilia A and B cannot be differentiated on clinical grounds. Laboratory tests include platelet count, prothrombin time, partial thromboplastin time, and bleeding time.
openaire +2 more sources
The clinical manifestations of hemophilia depend upon both age and the severity of the factor VIII or IX deficiency. Hemophilia A and B cannot be differentiated on clinical grounds. Laboratory tests include platelet count, prothrombin time, partial thromboplastin time, and bleeding time.
openaire +2 more sources
Blood Coagulation in Hemophilia A and Hemophilia C
Blood, 1998Tissue factor (TF)-induced coagulation was compared in contact pathway suppressed human blood from normal, factor VIII-deficient, and factor XI-deficient donors. The progress of the reaction was analyzed in quenched samples by immunoassay and immunoblotting for fibrinopeptide A (FPA), thrombin-antithrombin (TAT), factor V activation, and osteonectin ...
J B Lock +5 more
openaire +3 more sources
Prophylaxis for hemophilia A without inhibitors: treatment options and considerations
Expert Review of Hematology, 2020Introduction Hemophilia A is a bleeding disorder traditionally managed with standard half-life (SHL) factor (F) VIII concentrates. Extended half-life (EHL) FVIII products and emicizumab-kywh, a nonfactor therapy, are newer treatment options.
L. Valentino, K. Khair
semanticscholar +1 more source
A Challenge for Hemophilia Treatment: Hemophilia and Cancer
Journal of Pediatric Hematology/Oncology, 2020Background: The risk of developing cancer increases with age and also adverse environmental conditions. The same holds true in the aging people with hemophilia (PwH). Furthermore, cancer is an important challenge for physicians working in multidisciplinary hemophilia care centers. Aim:
Basak Koc, Bulent Zulfikar
openaire +3 more sources
JAMA: The Journal of the American Medical Association, 1983
Reproduction rates in 294 men with severe hemophilia, 327 of their mothers, and 215 of their sisters were compared with Vital Statistics data for the general US population matched for exact age, calendar year between 1940 and 1977, and, for women, parity.
Robert B. Francis, Carol K. Kasper
openaire +3 more sources
Reproduction rates in 294 men with severe hemophilia, 327 of their mothers, and 215 of their sisters were compared with Vital Statistics data for the general US population matched for exact age, calendar year between 1940 and 1977, and, for women, parity.
Robert B. Francis, Carol K. Kasper
openaire +3 more sources
2011
Acquired hemophilia A is a rare but often life-threatening hemorrhagic disorder characterized by an autoantibody directed against coagulation factor VIII. Fifty per cent of cases are idiopathic whereas the remaining 50% are associated with pregnancy, autoimmune conditions, malignancies and drugs.
Franchini M, LIPPI, Giuseppe
openaire +3 more sources
Acquired hemophilia A is a rare but often life-threatening hemorrhagic disorder characterized by an autoantibody directed against coagulation factor VIII. Fifty per cent of cases are idiopathic whereas the remaining 50% are associated with pregnancy, autoimmune conditions, malignancies and drugs.
Franchini M, LIPPI, Giuseppe
openaire +3 more sources